✦ LIBER ✦

Prevalence of fabry disease in malepatients with chronic renal disease not receiving renal replacement therapy: Preliminary report of a multicenter study

✍ Scribed by J.A. Herrero; M.S. Garciá Vinuesa; F. Garciá Martina; M.J. Arribas; R. Delgado; J.L. Teruel; C. Quereda; J.L. Miguel; J. Martínez-Ara; E. González Parra; A. Ortiz; J. González; J. Egido

Book ID: 117321737
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 121 KB
Volume: 29
Category: Article
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(07)80128-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predicting mortality and uptake of renal

Predicting mortality and uptake of renal replacement therapy in patients with stage 4 chronic kidney disease

✍ Conway, B.; Webster, A.; Ramsay, G.; Morgan, N.; Neary, J.; Whitworth, C.; Harty 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 163 KB

Definitions of progression in chronic ki

Definitions of progression in chronic kidney disease--predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up

✍ Marks, A.; Fluck, N.; Prescott, G. J.; Robertson, L. M.; Simpson, W. G.; Smith, 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 225 KB

Outcomes of patients with end-stage rena

Outcomes of patients with end-stage renal disease (ESRD) under chronic hemodialysis requiring continuous renal replacement therapy (CRRT) and patients without ESRD in acute kidney injury requiring CRRT: A single-center study

✍ Yeon Soon Jung; Junseop Lee; Ho Sik Shin; Hark Rim 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Progressive renal failure despite long-t

Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new α-galactosidase mutation of Leu311Arg (L311R)

✍ Keisuke Suzuki; Naoto Miura; Wataru Kitagawa; Shinkichi Suzuki; Atsushi Komatsud 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 414 KB

A comparative study of renal dysfunction

A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis

✍ Muhammad HAROON; Fahd ADEEB; Joe DEVLIN; Donncha O`GRADAIGH; Frank WALKER 📂 Article 📅 2011 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 91 KB

Efficacy and tolerability of intravenous

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease

✍ Anatole Besarab; Moro O. Salifu; N. Martin Lunde; Vinod Bansal; Steven Fishbane; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 1017 KB